NCT01631552

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: COMPLETED

Phase: PHASE1, PHASE2

Sponsor: Gilead Sciences

Condition: Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.